Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER versus HEPATASOL 8.
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER versus HEPATASOL 8.
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER vs HEPATASOL 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% in Dextrose 10% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories to prevent catabolism. The mechanism involves intravenous administration bypassing gastrointestinal tract, directly providing essential and non-essential amino acids for anabolism and energy in the form of glucose.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day by central line, providing 4.25% amino acids and 10% dextrose. Infusion rate typically 1-2 mL/min initially, adjusted to provide 1-1.5 g/kg/day of amino acids and 3-4 g/kg/day of dextrose.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
None Documented
None Documented
Not applicable as a fixed agent; amino acids have distribution half-life of 15-30 min; dextrose has elimination half-life of 1.5-2.5 hours depending on metabolic state.
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Amino acids are metabolized to urea and other nitrogenous wastes; renal excretion of metabolites accounts for >90% of nitrogen elimination, with <5% excreted unchanged in urine. Dextrose is fully metabolized to CO2 and water.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution